paclitaxel + carboplatin or cisplatin + 5-fluorouracil

This entry refers to two alternative multi-agent chemotherapy regimens used primarily in the treatment of various solid tumors. The first regimen combines paclitaxel (a microtubule inhibitor) with either carboplatin or cisplatin (both platinum-based DNA crosslinking agents). The second regimen includes cisplatin combined with 5-fluorouracil (an antimetabolite that inhibits thymidylate synthase). These combinations are standard-of-care for several cancers including ovarian, lung, cervical, endometrial, head and neck cancers. Paclitaxel disrupts microtubule function during cell division; carboplatin and cisplatin form DNA crosslinks leading to apoptosis; 5-fluorouracil inhibits DNA synthesis by blocking thymidylate synthase. These regimens are often chosen based on cancer type, patient tolerance to toxicity profiles (carboplatin is less nephrotoxic than cisplatin), and specific clinical scenarios[1][2][3][6].

Other names

paclitaxel and carboplatinpaclitaxel and cisplatin plus 5-fluorouracilTaxol/carboplatin or cisplatin/5-FU